HDAC inhibition, plus entinostat (MS-275), re-sensitized TKI-refractory NSCLC cell lines to gefitinib, most likely by recovering E-cadherin expression [106]. This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.